Brian Cheng
Stock Analyst at JP Morgan
(2.12)
# 2,966
Out of 5,049 analysts
68
Total ratings
48.15%
Success rate
-7.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $18.89 | +21.76% | 3 | Oct 16, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Underweight | n/a | $1.18 | - | 5 | Oct 10, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Underweight | n/a | $1.67 | - | 1 | Oct 10, 2025 | |
| ABSI Absci | Initiates: Overweight | n/a | $4.11 | - | 1 | Oct 2, 2025 | |
| IMVT Immunovant | Maintains: Overweight | $37 → $33 | $23.78 | +38.77% | 4 | Sep 30, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $41 → $47 | $41.90 | +12.17% | 2 | Sep 26, 2025 | |
| ROIV Roivant Sciences | Maintains: Overweight | $16 → $20 | $19.60 | +2.04% | 7 | Sep 18, 2025 | |
| CRSP CRISPR Therapeutics AG | Initiates: Overweight | $70 | $61.97 | +12.96% | 1 | Sep 18, 2025 | |
| PGEN Precigen | Upgrades: Neutral | n/a | $4.16 | - | 3 | Aug 15, 2025 | |
| IMNM Immunome | Maintains: Overweight | $23 → $22 | $17.00 | +29.41% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $34.30 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $75.95 | -24.95% | 5 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $13 | $13.07 | -0.54% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.06 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $28 | $13.94 | +100.86% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $6.88 | +379.65% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $2.42 | +147.93% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $125 | $9.44 | +1,224.15% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.66 | +2,007.16% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.18 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.73 | +721.92% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.00 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.39 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $9.30 | +813.98% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $6.86 | +206.12% | 1 | Aug 3, 2021 |
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $18.89
Upside: +21.76%
Allogene Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.18
Upside: -
Pliant Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.67
Upside: -
Absci
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $4.11
Upside: -
Immunovant
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $23.78
Upside: +38.77%
CG Oncology
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $41.90
Upside: +12.17%
Roivant Sciences
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $19.60
Upside: +2.04%
CRISPR Therapeutics AG
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $61.97
Upside: +12.96%
Precigen
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $4.16
Upside: -
Immunome
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $17.00
Upside: +29.41%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $34.30
Upside: -
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $75.95
Upside: -24.95%
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $13.07
Upside: -0.54%
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $3.06
Upside: -
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $13.94
Upside: +100.86%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $6.88
Upside: +379.65%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $2.42
Upside: +147.93%
Mar 19, 2024
Upgrades: Neutral
Price Target: $125
Current: $9.44
Upside: +1,224.15%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.66
Upside: +2,007.16%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.18
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.73
Upside: +721.92%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.00
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $2.39
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $9.30
Upside: +813.98%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $6.86
Upside: +206.12%